Every year, LexisNexis publishes a list that the financial and scientific world tends to treat as a quiet but credible report card on global innovation. The Top 100 Global Innovators ranking does not measure press releases or funding rounds or how many times a CEO appeared on a podcast. It is built on something harder to fake: measurable improvements in patent portfolio strength, analyzed across more than 17 million global patent families using the firm’s Patent Asset Index methodology. In other words, it tracks who is actually building things that are new and defensible.
This year, for the first time in the ranking’s history, Boston placed five companies on that list simultaneously. The five honorees are Moderna, Alnylam Pharmaceuticals, Flagship Pioneering, Orna Therapeutics, and SharkNinja — the largest group the metro has ever placed on the list. It is a record, and it arrived at a moment when the city’s innovation ecosystem is simultaneously celebrating its strengths and navigating some of its most serious headwinds in years.
Take a moment to sit with that list. Two of the world’s most sophisticated RNA therapeutics companies. The venture studio that essentially invented the modern biotech company-creation model. A circular RNA startup that was acquired for $2.4 billion weeks before the ranking came out. And a Needham-based kitchen appliance company whose ice cream maker broke the internet. That range — from molecular biology to frozen desserts — says something important about what Boston’s innovation economy actually looks like in 2026.
The ranking ties Boston with Los Angeles for third place among U.S. cities, behind Silicon Valley with 11 companies and New York City with 8. But the more striking figure is the hypothetical one: if Boston were a country, it would rank sixth in the world, behind the United States overall at 46, Germany at 9, China at 7, South Korea at 7, and Japan at 7. That means Greater Boston, a metro area of roughly 4.9 million people, is outperforming most sovereign nations when it comes to generating globally significant intellectual property.
The five companies themselves are worth examining individually, because each represents a different dimension of what makes Boston’s ecosystem tick.
Alnylam Pharmaceuticals and Moderna are the veterans — Cambridge institutions that have spent years converting cutting-edge RNA science into real therapies and real revenue. Alnylam essentially invented the field of RNA interference therapeutics and has spent two decades converting that scientific leadership into an approved product pipeline. Moderna needs less introduction: the COVID-19 vaccine that reached billions of people globally was developed, in large part, a few miles from Kendall Square.
Flagship Pioneering is something different entirely — not a single company but a company-creation engine. Founded in 2000, Flagship has fostered more than 100 scientific ventures and manages $14 billion in assets. It is the organization that founded Moderna, and it has been methodically applying the same playbook — identify a contrarian scientific hypothesis, build a company around it before anyone else sees it — across dozens of fields simultaneously. Being recognized as a global innovator in its own right, separate from the companies it has spawned, is a notable acknowledgment of how unusual its model actually is.
Orna Therapeutics represents the new wave: a smaller, specialist player whose focused capabilities in circular RNA therapy created outsized strategic relevance. The Watertown-based company was developing treatments that use circular RNA and lipid particles to trigger the body’s own immune defenses against disease. Its scientific approach was distinctive enough to attract Eli Lilly’s attention — the pharma giant acquired Orna last month in a deal valued at up to $2.4 billion. The fact that Orna made the global innovators list in the same month it was absorbed by one of the world’s largest pharmaceutical companies is a neat encapsulation of the Boston biotech lifecycle: build something genuinely new, get recognized, get acquired.
And then there is SharkNinja — the outlier on this list, and perhaps the most interesting honoree for exactly that reason. The Needham company is not curing diseases or advancing the frontiers of molecular biology. It is making vacuum cleaners and blenders and, most famously, the Ninja CREAMi — a countertop appliance that uses a distinct freezing and shaving process to turn solid frozen blocks into ice cream in minutes, a product that went viral on social media and drove the company’s revenue to new highs. SharkNinja’s appearance on a list dominated by pharma and semiconductor companies is a quiet reminder that innovation is not a single industry — it is a habit of building things that did not exist before.
All of this, it should be noted, is happening against a backdrop of genuine difficulty. Federal spending cuts, higher interest rates, tariff pressures, and a biotech funding environment that has been tightening since 2022 have created real strain across the Massachusetts life sciences sector. The 2026 LexisNexis report introduced 21 new entrants globally, reflecting the increasingly cross-sector nature of breakthrough innovation — a signal that Boston cannot rely exclusively on its biotech identity as other sectors and other cities close the gap.
But records have a way of reframing narratives. Five companies. One city. More first-time honorees than any other metro in the country. In a year when Boston’s innovation economy has faced its share of doubt, that is not a footnote — it is the headline.
